Selecta Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 08, 2019 08:00 ET
|
Selecta Biosciences, Inc.
- New strategic partnership with gene therapy leader, AskBio, to jointly develop next-generation AAV-based gene therapies to address the unmet medical need for repeat dosing in patients with rare and...
Selecta Biosciences Combines ImmTOR™ Platform with AskBio’s Industry-Leading Gene Therapy Platform in Strategic Partnership
August 07, 2019 07:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass. and RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced a...
Selecta Biosciences Announces Date of Second Quarter 2019 Financial Results Conference Call
August 01, 2019 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Present at Canaccord Genuity’s 39th Annual Growth Conference on August 7, 2019
July 31, 2019 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Appoints Alison Schecter, M.D., as Chief Medical Officer
July 15, 2019 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Announces Appointment of Scott D. Myers to Board of Directors
June 20, 2019 16:05 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., June 20, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Presents Full Data from Phase 2 Trial of SEL-212 for Chronic Refractory Gout at EULAR 2019
June 12, 2019 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., June 12, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Present at the Jefferies Healthcare Conference on June 06, 2019
May 30, 2019 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
Selecta Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 09, 2019 08:00 ET
|
Selecta Biosciences, Inc.
- Patient enrollment ongoing in COMPARE trial evaluating efficacy and safety of SEL-212 vs. KRYSTEXXA® in patients with chronic refractory gout; interim data expected in 4Q19 - - Preclinical data...
Selecta Biosciences to Announce Date of First Quarter 2019 Financial Results Conference Call
May 02, 2019 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...